Browse Articles

Discover research articles across all indexed journals

First-line (1L) camizestrant (CAMI) for emergent <i>ESR1</i> mutations ( <i>ESR1</i> m) in advanced breast cancer (ABC): Final progression-free survival 2 (PFS2) from the phase III SERENA-6 trial.

Journal of Clinical Oncology François Clément Bidard, Erica L. Mayer, Yeon Hee Park et al. Jun 10, 2026 DOI: 10.1200/jco.2026.44.17_suppl.lba1007

LBA1007 Background: CAMI is a next-generation SERD and complete ER antagonist. SERENA-6 enrolled patients (pts) with HR+/HER2− ABC receiving 1L aromatase inhibitor (AI) + CDK4/6i and without disease progression. Switching to CAMI, with continued CDK4/6i, at ESR1 m emergence during 1L AI + CDK4/6i significantly improved PFS (HR: 0.44 [95% CI: 0.31–0.60]; p&lt;0.0001; median follow-up: 12.6 mo). Here, we report the final PFS2 results. Methods: SERENA-6 was powered for PFS (primary endpoint) and the key secondary endpoint of investigator-assessed PFS2 (time from randomization to the earliest of disease progression after first subsequent therapy or death). Pts had scans to assess PFS2 every 8–12 weeks after first progression. PFS2 analysis was planned after ~158 PFS2 events (77% power to detect HR of 0.65) and analyzed using an adjusted log-rank test and a 2-sided significance level of ~5%. Chemotherapy/ADC-free survival was a secondary endpoint. Results: 157 pts were randomized to CAMI + CDK4/6i and 158 pts to AI + CDK4/6i. After 23.5 mo median follow-up (data cutoff: Jan 3, 2026), median PFS2 was 25.7 mo with CAMI + CDK4/6i vs 19.1 mo with AI + CDK4/6i; statistically significant improvement, HR: 0.63 (95% CI: 0.46–0.86); p=0.00373 (Table). Endocrine-based therapy was the most common first subsequent treatment (CAMI + CDK4/6i arm, 55.2%; AI + CDK4/6i arm, 66.7%). CAMI + CDK4/6i prolonged chemotherapy/ADC-free survival (HR: 0.64 [95% CI: 0.47–0.87]; nominal p=0.00375; Table) and TTD in GHS/QoL (0.48 [0.31–0.76]); nominal p&lt;0.001). PFS benefit with CAMI + CDK4/6i was maintained with longer follow-up (Table); 30-mo PFS rate was 30.4% vs 2.7% with continued AI + CDK4/6i. PFS benefit was not impacted by common co-mutations ( PIK3CA in 41.3% of pts, HR: 0.44 [95% CI: 0.28–0.68]; TP53 in 25.4% of pts, 0.49 [0.30–0.82]). At 30% maturity, OS HR was 0.87 (0.57–1.30). Safety was consistent with previous results. Conclusions: Switching to CAMI + CDK4/6i at ESR1 m emergence continued to result in PFS benefit, with approximately a third of pts still progression-free at 30 mo. PFS benefit was maintained beyond first progression; PFS2 was significantly improved and the clinically meaningful endpoint of chemotherapy/ADC-free survival was prolonged vs continuing AI + CDK4/6i. These results continue to support a switch to CAMI + CDK4/6i for pts with ESR1 m during 1L therapy to delay disease progression and deteriorations in QoL. Clinical trial information: NCT04964934 . DCO3 CAMI + CDK4/6i (n=157) AI + CDK4/6i (n=158) HR (95% CI) PFS Events, n (%)Median, mo24-mo rate, %30-mo rate, % 99 (63.1)16.834.930.4 124 (78.5)9.214.22.7 0.45 (0.34–0.59); p&lt;0.00001 PFS2 Events, n (%)Median, mo24-mo rate, %30-mo rate, % 80 (51.0)25.750.841.5 90 (57.0)19.136.329.7 0.63 (0.46–0.86); p=0.00373 Chemotherapy/ADC-free survival Events, n (%)Median, mo 85 (54.1)22.6 98 (62.0)18.7 0.64 (0.47–0.87); nominal p=0.00375

Glassy dynamics in active epithelia emerge from an interplay of mechanochemical feedback and crowding

Nature Communications Sindhu Muthukrishnan, Phanindra Dewan, Tanishq Tejaswi et al. Jun 10, 2026 DOI: 10.1038/s41467-026-74163-0

Correction to “Thiocyanate “Passivation” Unlocks Highly Selective and Efficient Acidic CO <sub>2</sub> Electroreduction to CH <sub>4</sub> on Cu-Based Catalysts”

Journal of the American Chemical Society Fangmu Wang, Hao Tian, Bing Nan et al. Jun 10, 2026 DOI: 10.1021/jacs.6c09852

Hierarchical semantic extraction and heterogeneous graph neural networks for event-driven time series forecasting

Scientific Reports Caichun Cen, Hongyan Liu, Beigu Hu et al. Jun 10, 2026 DOI: 10.1038/s41598-026-56483-9

Osimertinib with/without chemotherapy in patients with persistent ctDNA EGFR mutant (EGFRm) NSCLC at 3 weeks after 1L osimertinib: A randomized phase II study (FLAME study).

Journal of Clinical Oncology Zhijie Wang, Jia Zhong, Jianchun Duan et al. Jun 10, 2026 DOI: 10.1200/jco.2026.44.17_suppl.lba101

LBA101 Background: Persistent plasma ctDNA EGFR mutations (EGFRm) at 3 weeks after first-line osimertinib predict poor outcomes in advanced EGFR-mutated NSCLC. Though osimertinib plus chemotherapy outperformed osimertinib alone in the FLAURA2 trial, it remains unclear whether patients(pts) with persistent ctDNA EGFR mutations can benefit from this combination therapy. This study aims to evaluate the efficacy and safety of osimertinib plus chemotherapy versus osimertinib monotherapy in locally advanced or metastatic EGFRm NSCLC pts with persistence plasma ctDNA EGFRm at 3weeks of 1L osimertinib monotherapy. Methods: FLAME study is a multicenter, randomized controlled, phase II study in advanced NSCLC with EGFR Ex19del/L858R mutation who retain detectable plasma ctDNA EGFRm after 3 weeks of osimertinib. Plasma ctDNA EGFRm were analyzed by Super ARMS-PCR. Pts were randomized 1:1 to osimertinib plus carboplatin-pemetrexed or osimertinib monotherapy until progression or discontinuation criterion. The clinical data of screen failures patients were collected as part of real-world study. Randomization was stratified by CNS metastases (yes/no) and EGFRm subtype. The primary endpoint is investigator-assessed PFS per RECIST 1.1. Secondary endpoints include OS rate at 18 months, ORR, DCR, DoR, depth of response, safety and resistance profile. Exploratory endpoints: dynamic multi-omics biomarkers and quality of life. Data cutoff: 26 Jan 2026. Results: Of 448 screened pts with EGFRm, 134 had persistent plasma ctDNA EGFRm after 3 weeks of osimertinib. 80 pts were randomized to osimertinib plus chemotherapy (n=40) or continued osimertinib monotherapy (n=40). Baseline characteristics were generally balanced across arms (osimertinib plus chemotherapy/osimertinib): median age, 58/61 years; 60/55% female; 53/50% Ex19del; 48/50% L858R; 35/35% CNS metastases. Osimertinib plus chemotherapy significantly improved PFS versus osimertinib monotherapy (HR 0.53; 95% CI 0.31, 0.92; p=0.024; 67.5% maturity). Median PFS was 23.1 vs.12.7 months. ORR per investigator assessment was 50% vs. 35%, and median DoR was 15.6 months and 10.5 months, respectively. Grade≥3 treatment related adverse events (TRAEs) were higher in the combination group (65% vs. 10%) but manageable; no new safety signals were identified. Conclusions: This is the first perspective randomized controlled trial showing osimertinib plus chemotherapy significantly prolongs PFS versus osimertinib in pts who exhibit persistent ctDNA EGFR mutation at 3 weeks after 1L osimertinib monotherapy. This study provides prospective evidence for individualized escalation combination therapy based on dynamic molecular detection. Funded by AstraZeneca; ClinicalTrials.gov number, NCT04769388. Clinical trial information: NCT04769388 .

Nanometre-precision terahertz interferometry for battery electrode metrology

Nature Communications Guseon Kang, Jaeyoon Kim, Mee-Ree Kim et al. Jun 10, 2026 DOI: 10.1038/s41467-026-74193-8

Abstract High-precision, non-destructive thickness measurement is essential for lithium-ion battery (LIB) manufacturing. Existing approaches, such as X-rays, acoustic waves, and optical lasers, are limited by speed, resolution, or penetration into conductive materials. Here, we demonstrate nanometre-precision thickness measurements of LIB electrodes using terahertz (THz) Fabry–Pérot (FP) interferometry referenced to a photonic frequency comb. Combining the comb’s SI-traceable frequency accuracy with THz radiation’s immunity to scattering and absorption, our system directly detects FP modes with sub-10 MHz precision at sweep rates exceeding 12 THz/s, while spectral analysis simultaneously yields the complex refractive index. Electrode thicknesses of 50–150 μm are measured with nanometre precision: 70.1 nm (anode) and 465.5 nm (cathode) at 0.2 s, improving to 7.8 nm and 25.2 nm at 25.6 s, representing a one-to-two orders of magnitude improvement over temporal-analysis methods. The system further supports 3D profiling and dynamic thickness monitoring, enabling a unified, calibration-free platform for next-generation LIB metrology.

Controlling the Flow of Charges across Phthalocyanine@Transition-Metal Dichalcogenide Interfaces

Journal of the American Chemical Society Elena A. Mack, Elias Harrer, Florian Winkler et al. Jun 10, 2026 DOI: 10.1021/jacs.6c00882

Machine learning–enabled ECG arrhythmia classification: a systematic and educational study from signal processing to decision support

Scientific Reports Negin Melek Jun 10, 2026 DOI: 10.1038/s41598-026-56828-4

Reply to: Quizartinib for Newly Diagnosed <i>FLT3</i> -Internal Tandem Duplication–Negative AML

Journal of Clinical Oncology Pau Montesinos, Jorge Labrador, Pilar Lloret-Madrid Jun 10, 2026 DOI: 10.1200/jco-26-00338

Infection-induced glucose starvation triggers NINJ1-dependent macrophage lysis and Candida escape

Nature Communications Harshini Weerasinghe, Orawan Tulyaprawat, Helen Stölting et al. Jun 10, 2026 DOI: 10.1038/s41467-026-74195-6

Direct Alkane–Benzene Coupling Reactions with Bifunctional Zeolite-Encapsulated Metal Catalysts with Subnanoscale Intimacy

Journal of the American Chemical Society Hongtao Wang, Minghao Gao, Wenying Li et al. Jun 10, 2026 DOI: 10.1021/jacs.5c21822

Radiomics-based fundus autofluorescence analysis in central serous chorioretinopathy–MICRoN report number twelve

Scientific Reports Elham Sadeghi, Lingyi Peng, Shreyaa Rohindra Lall et al. Jun 10, 2026 DOI: 10.1038/s41598-026-56995-4

Izalontamab brengitecan (iza-bren) versus physician’s choice of chemotherapy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC): A randomized phase III study.

Journal of Clinical Oncology Jiong Wu, Jian Zhang, Quchang Ouyang et al. Jun 10, 2026 DOI: 10.1200/jco.2026.44.17_suppl.lba1003

LBA1003 Background: Triple-negative breast cancer (TNBC) remains a therapeutic challenge due to its aggressive biology and limited treatment options beyond first-line immunotherapy plus chemotherapy. Patients who progress after taxane-containing regimens face poor outcomes and have a high unmet need. Izalontamab brengitecan (iza-bren) is a first-in-class bispecific antibody–drug conjugate (ADC) targeting EGFRxHER3 with a potent topoisomerase I inhibitor payload. Here we report the results of a pre-planned interim analysis from a phase III study of iza-bren in patients with TNBC. Methods: This randomized, multicenter, open-label, phase III study enrolled patients with unresectable locally advanced or metastatic TNBC who had disease progression after 1–2 prior lines of systemic therapy for advanced disease—including prior taxanes. Patients were randomized 1:1 to receive iza-bren (2.5 mg/kg D1D8 Q3W) or treatment of physician’s choice (TPC) (eribulin, capecitabine, gemcitabine, or vinorelbine). Randomization was stratified by prior lines of therapy (1 vs. 2), prior anti-PD-(L)1 (yes vs. no), and HER2 IHC (0 vs. 1+/2+ ISH-). The dual-primary endpoints were progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS). Results: A total of 418 patients were randomized (iza-bren/TPC: 207/211) and 412 were treated (iza-bren/TPC: 207/205). As of the data cutoff (Jan 13, 2026), median follow-up was 11.0 months. The median PFS by BICR was 8.5 months with iza-bren and 3.1 months with TPC (HR, 0.29 [95% CI, 0.22-0.38]; stratified log-rank P&lt;0.0001). The median OS was 15.9 months with iza-bren and 12.5 months with TPC (HR, 0.60 [95% CI, 0.42-0.85]; stratified log-rank P=0.0019). The confirmed objective response rate (cORR) assessed by BICR was 51.7% with iza-bren and 20.5% with TPC (odds ratio, 4.28 [95% CI, 2.75-6.66]). Most common grade ≥3 TEAEs (iza-bren vs TPC) were neutrophil count decreased (58.0% vs 46.8%), white blood cell count decreased (56.0% vs 33.2%), platelet count decreased (52.7% vs 2.4%), and anemia (46.9% vs 3.9%). All-grade ILD was reported in 3 (1.4%) and 0 patients in the iza-bren and TPC arms, respectively. Treatment discontinuation due to TEAEs occurred in 4 (1.9%) patients in the iza-bren arm and 1 (0.5%) patient in the TPC arm. No new safety signals were observed. Conclusions: This pre-planned interim analysis met both dual-primary endpoints of PFS by BICR and OS. Iza-bren demonstrated a statistically significant and clinically meaningful improvement in both PFS and OS compared with chemotherapy, with a manageable safety profile in heavily pre-treated TNBC patients, supporting iza-bren as a new standard of care in this population. Clinical trial information: NCT06382142 .

Capture, storage, and re-use of liquid hydrogen boil-off for aviation and aerospace applications

Nature Communications Peng Peng, Cullen Quine, Tanumoy Banerjee et al. Jun 10, 2026 DOI: 10.1038/s41467-026-74294-4

Multiple Superconducting Phases in <i>m</i> -TaS <sub>3</sub> under Extreme Compression

Journal of the American Chemical Society Xindeng Lv, Zhenfang Xing, Si Wu et al. Jun 10, 2026 DOI: 10.1021/jacs.6c03117

Mitochondrially Transcribed DsRNA Mediates Manganese-Induced Neuroinflammation

Journal of Neuroscience Hadassah Mendez-Vazquez, Avanti Gokhale, Maureen M. Sampson et al. Jun 10, 2026 DOI: 10.1523/jneurosci.1936-25.2026

Manganese is an essential trace element required for various biological functions but in excess is neurotoxic and leads to significant health concerns. The mechanisms underlying manganese neurotoxicity remain poorly understood. Neuropathological studies of affected brain regions reveal astrogliosis, neuronal loss, and neuroinflammation. Here, we present a novel manganese-dependent mechanism linking mitochondrial dysfunction to neuroinflammation. We found that manganese disruption of the mitochondrial transcriptome processing results in the accumulation of double-stranded RNA (dsRNA). This dsRNA is released into the cytoplasm, where it activates the cytosolic sensor MDA5, triggering type I interferon responses and inflammatory cytokine production. This mechanism is evident in 100 d human cerebral organoids, where manganese increased mitochondrial dsRNA and induced inflammatory responses in mature astrocytes. Similarly, we observed an increase in mitochondrial dsRNA content, the activation of an inflammatory transcriptome and the production of cytokines in female and male mouse brains carrying mutations in the Slc30a10 gene, a model for human hypermanganesemia with dystonia 1 disorder. These findings highlight the previously unrecognized role of mitochondrial dsRNA in manganese-induced neuroinflammation and provide insights into the molecular pathogenesis of manganism. We propose that this mitochondrial dsRNA-induced inflammatory pathway could be active in other neurological diseases caused by environmental or genetic factors.

Synthesis, biological evaluation and detailed computational studies of N-sulfonyl indole-based dihydrothiazoles against colorectal carcinoma

Scientific Reports Zahra Batool, Iqra Naseer, Şeyma Ateşoğlu et al. Jun 10, 2026 DOI: 10.1038/s41598-026-56442-4

SUPPORT+ digital self-management and clinical support for advanced cancer: A randomized controlled trial.

Journal of Clinical Oncology Wing-Lok Chan, Inda Sung Soong, Mei Ying Lim et al. Jun 10, 2026 DOI: 10.1200/jco.2026.44.17_suppl.lba12008

LBA12008 Background: Patients with advanced cancer often experience distressing symptoms that impair HRQoL and lead to emergency department (ED) visits and hospitalizations. Digital symptom-monitoring tools enable earlier detection of symptoms, yet evidence in palliative care remains limited. This study evaluated whether SUPPORT+, a mobile app incorporating weekly symptom reporting using the Integrated Palliative Care Outcome Scale (IPOS), automated self-management guidance, and nurse follow-up for severe symptoms, improves outcomes when added to usual care for community-dwelling patients with advanced cancer. Methods: A multi-centre RCT was conducted across 6 palliative care clinics in Hong Kong (Jan 2023–Feb 2025). Patients with advanced cancers no longer receiving systemic treatment were randomized 1:1 to SUPPORT+ or usual care for 18 weeks. The primary outcome was change in HRQoL (EQ-5D-5L). Secondary outcomes included ECOG PS, ED visits, and hospitalizations. Results: A total of 633 patients were enrolled (315 intervention; 318 control), median age 79 (range 31–103), with 47.4% male. HRQoL was better maintained in SUPPORT+: EQ-5D-5L index declined from 0.59 at baseline to 0.52 at week 18 vs. 0.62 to 0.37 in usual care (mean difference −0.18; p&lt;0.001). EQ-VAS remained more stable (68.7 to 65.8 vs. 68.9 to 59.5; mean difference −6.54, p&lt;0.001). ECOG PS deterioration was less common (12.4% vs. 18.9%; p=0.016). ED visits were similar. Hospitalization outcomes favoured SUPPORT+, with more reductions in admissions and shorter lengths of stay (both p≤0.001). Conclusions: SUPPORT+ maintained HRQoL, preserved PS, and reduced hospitalizations in advanced cancer. Digital symptom monitoring with automated self-management and timely healthcare support is a promising strategy to strengthen community-based supportive care. Clinical trial information: HKUCTR-3116. Proportion of patients in the SUPPORT+ arm and control (usual care) arm with changes in HRQoL, self-efficacy, emergency department visit, hospitalization episodes and duration. Intervention Group N=315 Control Group N=318 P-value no. % no. % Primary Endpoint: EQ-5D-5L index (change ≥0.11) Improved 59 18.73% 14 4.4% &lt;0.001 No change 137 43.49% 129 40.57% Worsen 119 37.78% 175 55.03% EQ-5D-5L VAS (change ≥6) Improved 80 25.40% 48 15.09% 0.002 No change 114 36.19% 112 35.22% Worsen 121 38.41% 158 49.69% Secondary Endpoints: Self-efficacy Improved 121 38.41% 65 20.44% &lt;0.001 No change 18 5.71% 26 8.18% Worsen 176 55.87% 227 71.38% Emergency Department Visits Reduced 85 26.98% 76 23.90% 0.167 No change 171 54.29% 163 51.26% Increased 59 18.73% 79 24.84% Hospitalization Episodes Reduced 89 28.25% 70 22.01% 0.001 No change 174 55.24% 157 49.37% Increased 52 16.51% 91 28.62% Hospitalization Days Reduced 98 31.11% 70 22.01% &lt;0.001 No change 162 51.43% 136 42.77% Increased 55 17.46% 112 35.22% ECOG Improved 6 1.90% 13 4.09% 0.016 No change 270 85.71% 245 77.04% Worsen 39 12.38% 60 18.87%

Imaging of a van der Waals spin-orbit torque system using spin ensembles in hBN

Nature Communications Xi Zhang, Jingcheng Zhou, Chaowei Hu et al. Jun 10, 2026 DOI: 10.1038/s41467-026-74178-7

Abstract Recently, optically active spin defects embedded in two-dimensional (2D) van der Waals (vdW) crystals have emerged as a transformative quantum sensing platform to explore cutting-edge materials science. Taking advantage of excellent solid-state integrability, this new class of spin defects can be readily arranged in nanoscale proximity to target materials, showing great promise for realizing in-situ quantum sensing of microscopic spin and charge behaviors in vdW heterostructures. Here we report hexagonal boron nitride-based quantum imaging of field-free deterministic magnetic switching and electric current distributions in an all-vdW spin-orbit torque (SOT) system. By visualizing variations of nanoscale magnetic stray field profile of room-temperature 2D magnet Fe 3 GaTe 2 under different SOT conditions, we show how the magnetic switching evolves from deterministic to stochastic behavior due to the interplay between spin orientations, anisotropy and Joule heating. Micromagnetic simulations rationalize our results well, revealing the role of field-like SOT in inhibiting thermal fluctuation driven stochastic switching and chaotic multi-domain competition. This understanding, which is otherwise difficult to access by conventional transport measurements, offers valuable insights into material design, testing, and performance evaluation of next-generation vdW spintronic devices.

Ladderanes: Stepping Up as Nonclassical <i>ortho</i> -Substituted Benzene Bioisosteres

Journal of the American Chemical Society Souvik Adak, Verónica Muñoz-Canales, Surya Sekhar Manna et al. Jun 10, 2026 DOI: 10.1021/jacs.6c05064